GILD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
Navigating Challenges To Shape A Robust Future In Biotech And Healthcare Innovation
US$83.0
FV
7.8% undervalued intrinsic discount1.75%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
9 days agoauthor updated this narrative
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.49 |
| 52 Week High | US$87.87 |
| 52 Week Low | US$62.07 |
| Beta | 0.20 |
| 11 Month Change | 11.83% |
| 3 Month Change | 18.08% |
| 1 Year Change | 1.27% |
| 33 Year Change | 10.38% |
| 5 Year Change | 18.00% |
| Change since IPO | 11,987.32% |
Recent News & Updates
A Look At Gilead Sciences After Its Recent Weakness
Jul 27Gilead Records Positive Phase III Results In HIV
Jun 22Recent updates
A Look At Gilead Sciences After Its Recent Weakness
Jul 27Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Gilead Sciences: Realizing Financial Projections Is Key
Mar 20Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
Mar 01Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77
Feb 28We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated
Feb 15Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77
Feb 13Gilead Sciences: Cheap For A Reason
Feb 10Gilead Sciences: The Sky Is Not Falling
Feb 01Shareholder Returns
| GILD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.03% | -1.0% | 0.3% |
| 1Y | 1.3% | 16.3% | 18.6% |
Return vs Industry: GILD underperformed the US Biotechs industry which returned 16.3% over the past year.
Return vs Market: GILD underperformed the US Market which returned 18.6% over the past year.
Price Volatility
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GILD has not had significant price volatility in the past 3 months.
Volatility Over Time: GILD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILD fundamental statistics | |
|---|---|
| Market cap | US$94.76b |
| Earnings (TTM) | US$485.00m |
| Revenue (TTM) | US$27.45b |
196.5x
P/E Ratio3.5x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILD income statement (TTM) | |
|---|---|
| Revenue | US$27.45b |
| Cost of Revenue | US$6.17b |
| Gross Profit | US$21.28b |
| Other Expenses | US$20.80b |
| Earnings | US$485.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 77.52% |
| Net Profit Margin | 1.77% |
| Debt/Equity Ratio | 144.3% |
How did GILD perform over the long term?
See historical performance and comparison